Mattias Carlsten

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Se sidan på engelska [1]
Tema: Att delta i forskning [2]
[1] http://ki.se/en/people/mattca
[2] http://ki.se/forskning/tema-att-delta-i-forskning

Artiklar

Article: CURRENT PROTOCOLS. 2024;4(11):e70040
Optimizing CAR-NK Cell Transduction and Expansion: Leveraging Cytokine Modulation for Enhanced Performance.
Ingegnere T; Segain B; Cozzani A; Carlsten M; Mitra S; Gaggero S
Article: MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT. 2024;32(2):101225
Endovascular transplantation of mRNA-enhanced mesenchymal stromal cells results in superior therapeutic protein expression in swine heart
Al-Saadi J; Walden M; Sandell M; Sohlmer J; Grankvist R; Friberger I; Andersson A; Carlsten M; Chien K; Lundberg J; Witman N; Holmin S
Article: NPJ PRECISION ONCOLOGY. 2024;8(1):108
Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity
Sanz-Ortega L; Leijonhufvud C; Schoutens L; Lambert M; Levy E; Andersson A; Wahlin BE; Carlsten M
Article: LEUKEMIA. 2024;38(3):579-589
Harnessing upregulated E-selectin while enhancing SDF-1α sensing redirects infused NK cells to the AML-perturbed bone marrow
Sanz-Ortega L; Andersson A; Carlsten M
Article: JOURNAL OF IMMUNOLOGY. 2024;212(5):868-880
KIR2DS1 and KIR2DL1-C245 Dominantly Repress NK Cell Degranulation Triggered by Monoclonal or Bispecific Antibodies, whereas Education by Uptuning Inhibitory Killer Ig-related Receptors Exerts No Advantage in Ab-dependent Cellular Cytotoxicity
Leijonhufvud C; Sanz-Ortega L; Schlums H; Gaballa A; Andersson A; Eriksson C; Segerberg F; Uhlin M; Bryceson YT; Carlsten M
Article: LEUKEMIA. 2023;37(9):1830-1841
Perturbed epigenetic transcriptional regulation in AML with IDH mutations causes increased susceptibility to NK cells
Palau A; Segerberg F; Lidschreiber M; Lidschreiber K; Naughton AJ; Needhamsen M; Jung LA; Jagodic M; Cramer P; Lehmann S; Carlsten M; Lennartsson A
Article: EJNMMI RESEARCH. 2023;13(1):73
Comparative in vivo biodistribution of cells labelled with [⁸⁹Zr]Zr-(oxinate)₄ or [⁸⁹Zr]Zr-DFO-NCS using PET
Friberger I; Nilsson JNN; Lu L; Siikanen J; Ardenfors O; Milton S; Samen E; Goos JACM; Carlsten M; Holmin S; Tran TAA
Article: HAEMATOLOGICA. 2022;107(8):1786-1795
A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells in vitro and in vivo
Arruda LCM; Stikvoort A; Lambert M; Jin L; Rivera LS; Alves RMP; de Moura TR; Mim C; Lehmann S; Axelsson-Robertson R; Dick JE; Mattsson J; Onfelt B; Carlsten M; Uhlin M
Article: BLOOD ADVANCES. 2022;6(11):3352-3366
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses
Daly J; Sarkar S; Natoni A; Stark JC; Riley NM; Bertozzi CR; Carlsten M; O'Dwyer ME
Article: VIRCHOWS ARCHIV. 2022;480(3):655-666
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
Merrien M; Wasik AM; Ljung E; Morsy MHA; Rodrigues JDM; Carlsten M; Rassidakis GZ; Christensson B; Kolstad A; Jerkeman M; Ek S; Herold N; Wahlin BE; Sander B
Article: MOLECULAR IMAGING AND BIOLOGY. 2021;23(6):952-962
Optimisation of the Synthesis and Cell Labelling Conditions for [⁸⁹Zr]Zr-oxine and [⁸⁹Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications
Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samen E; Carlsten M; Holmin S; Tran TA
Article: BMC CANCER. 2021;21(1):500
The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome
Noring K; Carlsten M; Sonnevi K; Wahlin BE
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(10):e1346
LIR-1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody-dependent cellular cytotoxicity
Leijonhufvud C; Reger R; Segerberg F; Theorell J; Schlums H; Bryceson YT; Childs RW; Carlsten M
Article: METHODS IN MOLECULAR BIOLOGY. 2020;2121:213-239
CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2164
Autoantibodies to Killer Cell Immunoglobulin-Like Receptors in Patients With Systemic Lupus Erythematosus Induce Natural Killer Cell Hyporesponsiveness
Segerberg F; Lundtoft C; Reid S; Hjorton K; Leonard D; Nordmark G; Carlsten M; Hagberg N
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:1262
Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4^R334X
Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
Article: ONCOIMMUNOLOGY. 2019;8(2):e1534664
Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5
Carlsten M; Namazi A; Reger R; Levy E; Berg M; St Hilaire C; Childs RW
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2019;8:7
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016
Carlsten M; Jadersten M; Hellstrom A; Littmann K; Melen CM; Junlen HR; Sonnevi K; Ljungman P; Bjorkstrand B; Wahlin BE
Article: CLINICAL CANCER RESEARCH. 2018;24(8):1834-1844
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
Bjorklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikstrom K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellstrom-Lindberg E; Ljunggren H-G; Malmberg K-J
Article: PLOS ONE. 2018;13(8):e0202651
Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up
Hagstrom H; Andreasson A; Carlsson AC; Jerkeman M; Carlsten M
Article: CLINICAL CANCER RESEARCH. 2016;22(21):5211-5222
Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
Carlsten M; Korde N; Kotecha R; Reger R; Bor S; Kazandjian D; Landgren O; Childs RW
Article: METHODS IN MOLECULAR BIOLOGY. 2016;1441:231-240
mRNA Transfection to Improve NK Cell Homing to Tumors.
Levy ER; Carlsten M; Childs RW
Article: FRONTIERS IN IMMUNOLOGY. 2016;7:105
Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19
Carlsten M; Levy E; Karambelkar A; Li L; Reger R; Berg M; Peshwa MV; Childs RW
Article: JOURNAL OF IMMUNOLOGY. 2015;194(9):4518-4527
Coordinated Expression of DNAM-1 and LFA-1 in Educated NK Cells
Enqvist M; Ask EH; Forslund E; Carlsten M; Abrahamsen G; Beziat V; Andersson SA; Schaffer M; Spurkland A; Bryceson Y; Onfelt B; Malmberg K-J
Article: MOLECULAR THERAPY. 2014;22(7):1388-1395
Ultra-low Dose Interleukin-2 Promotes Immune-m_odulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers
Ito S; Bollard CM; Carlsten M; Melenhorst JJ; Biancotto A; Wang E; Chen J; Kotliarov Y; Cheung F; Xie Z; Marincola F; Tanimoto K; Battiwalla M; Olnes MJ; Perl S; Schum P; Hughes TE; Keyvanfar K; Hensel N; Muranski P; Young NS; Barrett AJ
Article: INTERNATIONAL JOURNAL OF CANCER. 2013;133(7):1643-1652
Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
Wennerberg E; Sarhan D; Carlsten M; Kaminskyy VO; D'Arcy P; Zhivotovsky B; Childs R; Lundqvist A
Article: JOURNAL OF IMMUNOLOGY. 2011;187(7):3546-3554
Selenite Induces Posttranscriptional Blockade of HLA-E Expression and Sensitizes Tumor Cells to CD94/NKG2A-Positive NK Cells
Enqvist M; Nilsonne G; Hammarfjord O; Wallin RPA; Bjoerkstroem NK; Bjornstedt M; Hjerpe A; Ljunggren H-G; Dobra K; Malmberg K-J; Carlsten M
Article: LEUKEMIA. 2010;24(9):1607-1616
Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34⁺ blasts in myelodysplastic syndrome
Carlsten M; Baumann BC; Simonsson M; Jadersten M; Forsblom A-M; Hammarstedt C; Bryceson YT; Ljunggren H-G; Hellstrom-Lindberg E; Malmberg K-J
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2009;390(4):1272-1277
Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides
Curbo S; Gaudin R; Carlsten M; Malmberg K-J; Troye-Blomberg M; Ahlborg N; Karlsson A; Johansson M; Lundberg M
Article: JOURNAL OF IMMUNOLOGY. 2009;183(8):4921-4930
Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells
Carlsten M; Norell H; Bryceson YT; Poschke I; Schedvins K; Liunggren H-G; Kiessling R; Malmberg K-J
Article: JOURNAL OF IMMUNOLOGY. 2008;181(9):6010-6019
Estimation of the Size of the Alloreactive NK Cell Repertoire: Studies in Individuals Homozygous for the Group A KIR Haplotype
Fauriat C; Andersson S; Bjorklund AT; Carlsten M; Schaffer M; Bjorkstrom NK; Baumann BC; Michaelsson J; Ljunggren H-G; Malmberg K-J
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2007;56(7):973-984
A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients
Hanson MGV; Ozenci V; Carlsten MCV; Glimelius BL; Frodin J-EA; Masucci G; Malmberg K-J; Kiessling RVR
Article: CANCER RESEARCH. 2007;67(3):1317-1325
DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells
Carlsten M; Bjorkstrom NK; Norell H; Bryceson Y; van Hall T; Baumann BC; Hanson M; Schedvins K; Kiessling R; Ljunggren H-G; Malmberg KJ
Article: CANCER RESEARCH. 2006;66(12):6387-6394
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity
Norell H; Carlsten M; Ohlum T; Malmberg K-J; Masucci G; Schedvins K; Altermann W; Handke D; Atkins D; Seliger B; Kiessling R
Article: JOURNAL OF CLINICAL INVESTIGATION. 2002;110(10):1515-1523
IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism
Malmberg KJ; Levitsky V; Norell H; de Matos CT; Carlsten M; Schedvins K; Rabbani H; Moretta A; Söderström K; Levitskaya J; Kiessling R
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2001;276(32):30542-30551
The core promoter of human thioredoxin reductase 1
Rundlöf AK; Carlsten M; Arnér ESJ
Article: BIOCHEMICAL JOURNAL. 2000;347(Pt 3):661-668
Prominent expression of the selenoprotein thioredoxin reductase in the medullary rays of the rat kidney and thioredoxin reductase mRNA variants differing at the 5′untranslated region
Rundlöf AK; Carlsten M; Giacobini MMJ; Arnér ESJ
Visa fler

Alla övriga publikationer

Letter: HEMASPHERE. 2023;7(11):e974
Improved Leukemia Clearance After Adoptive Transfer of NK Cells Expressing the Bone Marrow Homing Receptor CXCR4^R334X
Segerberg F; Lambert M; Sanz-Ortega L; Andersson A; Childs RW; Carlsten M
Editorial comment: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2023;8(1):316
Rough operators: sphingomyelinase inhibitors spike NK cells to kill cancer
Carlsten M; Bryceson YT
Conference publication: BRITISH JOURNAL OF HAEMATOLOGY. 2023;201:114-115
Redirecting NK cells to the lymph nodes to augment their lymphoma-targeting capacity
Schoutens L; Sanz-Ortega L; Leijonhufvud C; Lambert M; Levy E; Andersson A; Wahlin B; Carlsten M
Corrigendum: MOLECULAR IMAGING AND BIOLOGY. 2022;24(3):510
Optimisation of the Synthesis and Cell Labelling Conditions for [89Zr]Zr-oxine and [89Zr]Zr-DFO-NCS: a Direct In Vitro Comparison in Cell Types with Distinct Therapeutic Applications (vol 23, pg 952, 2021)
Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samen E; Carlsten M; Holmin S; Tran TA
Review: FRONTIERS IN IMMUNOLOGY. 2020;11:621225
Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy
Gaggero S; Witt K; Carlsten M; Mitra S
Review: FRONTIERS IN IMMUNOLOGY. 2019;10:2357
Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
Carlsten M; Jaras M
Review: FRONTIERS IN IMMUNOLOGY. 2019;10:1047
Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer
Daly J; Carlsten M; O'Dwyer M
Review: SEMINARS IN IMMUNOLOGY. 2017;31:20-29
Natural killer cell-mediated immunosurveillance of human cancer
Malmberg K-J; Carlsten M; Bjorklund A; Sohlberg E; Bryceson YT; Ljunggren H-G
Corrigendum: BLOOD CANCER JOURNAL. 2015;5(7):e321
The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies (vol 5, e306, 2015)
Dosani T; Carlsten M; Maric I; Landgren O
Review: NATURE REVIEWS DRUG DISCOVERY. 2015;14(7):487-498
Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens
Childs RW; Carlsten M
Review: FRONTIERS IN IMMUNOLOGY. 2015;6:266
Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications
Carlsten M; Childs RW
Letter: HAEMATOLOGICA. 2014;99(6):e81-e83
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Korde N; Carlsten M; Lee M-J; Minter A; Tan E; Kwok M; Manasanch E; Bhutani M; Tageja N; Roschewski M; Zingone A; Costello R; Mulquin M; Zuchlinski D; Maric I; Calvo KR; Braylan R; Tembhare P; Yuan C; Stetler-Stevenson M; Trepel J; Childs R; Landgren O
Thesis / dissertation: 2010
Molecular specificities of NK cell-mediated recognition of human tumor cells
Carlsten, Mattias
Review: INTERNATIONAL JOURNAL OF CANCER. 2009;124(4):757-762
Natural killer cell-mediated lysis of freshly isolated human tumor cells
Carlsten M; Malmberg K-J; Ljunggren H-G
Published conference paper: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2008;57(10):1541-1552
NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy
Malmberg K-J; Bryceson YT; Carlsten M; Andersson S; Bjorklund A; Bjorkstrom NK; Baumann BC; Fauriat C; Alici E; Dilber MS; Ljunggren H-G

Anställningar

Anknuten till Forskning, Laboratoriemedicin, Karolinska Institutet, 2024-2027

Examina och utbildning

Docent, hematologi, Karolinska Institutet, 2022
Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2010
Läkarexamen, Karolinska Institutet, 2007

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI